SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001410578-22-001250
Filing Date
2022-05-10
Accepted
2022-05-10 16:07:28
Documents
48
Period of Report
2022-03-31

Document Format Files

Seq Description Document Type Size
1 10-Q acxp-20220331x10q.htm   iXBRL 10-Q 948047
2 EX-31.1 acxp-20220331xex31d1.htm EX-31.1 14879
3 EX-31.2 acxp-20220331xex31d2.htm EX-31.2 14944
4 EX-32.1 acxp-20220331xex32d1.htm EX-32.1 6459
5 EX-32.2 acxp-20220331xex32d2.htm EX-32.2 6480
  Complete submission text file 0001410578-22-001250.txt   3125690

Data Files

Seq Description Document Type Size
6 EX-101.SCH acxp-20220331.xsd EX-101.SCH 28470
7 EX-101.CAL acxp-20220331_cal.xml EX-101.CAL 15213
8 EX-101.DEF acxp-20220331_def.xml EX-101.DEF 110022
9 EX-101.LAB acxp-20220331_lab.xml EX-101.LAB 224689
10 EX-101.PRE acxp-20220331_pre.xml EX-101.PRE 197549
42 EXTRACTED XBRL INSTANCE DOCUMENT acxp-20220331x10q_htm.xml XML 253875
Mailing Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305
Business Address 259 LIBERTY AVENUE STATEN ISLAND NY 10305 917-533-1469
Acurx Pharmaceuticals, Inc. (Filer) CIK: 0001736243 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40536 | Film No.: 22909581
SIC: 2834 Pharmaceutical Preparations